trending Market Intelligence /marketintelligence/en/news-insights/trending/pUe4ctCOsz7-WPY3-qXOiA2 content esgSubNav
In This List

Heron Therapeutics prices $150M common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Heron Therapeutics prices $150M common stock offering

Heron Therapeutics Inc. priced a previously announced underwritten public offering of $150 million worth of shares.

Heron intends to use proceeds from the transaction for general corporate purposes, including funding its ongoing and future clinical trials for postoperative opioid HTX-011.

The company also granted the underwriter of the offering a 30-day option to purchase up to an additional $22.5 million of the common shares.

The offering is expected to close by Dec. 7, with Cantor Fitzgerald & Co. serving as its sole book-running manager.